Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1

The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4

Efficacy

EUCRISA has proven efficacy across all primary and secondary endpoints1,2

See more

Safety Data

Learn more about the safety data of EUCRISA from the 4-week pivotal trials and open-label safety extension study1,3

See more

Dosing

EUCRISA can be applied to the skin anywhere on the face and body1

For topical use only.
Not for ophthalmic, oral,
or intravaginal use.

See more

Quick Links

*See Terms and Conditions here. Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $700 per tube. Annual savings up to $2,800. This Card will be accepted only at participating pharmacies. This Card is not health insurance. Pfizer Inc. PO Box 29387, Mission, KS 66201 1-866-382-7472.

References

  1. EUCRISA® (crisaborole) Full Prescribing Information. October 2017.
  2. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.
  3. Data on File. Pfizer Inc, New York, NY.